Publications by authors named "C Kerner"
Introduction: Fistula is a common complication of Crohn's disease (CD). Treatment with biologics has been associated with fistula healing. Long-term persistence is an important factor for a chronic inflammatory process such as fistula.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluates treatment persistence of ulcerative colitis patients using advanced therapies, specifically comparing those new to treatment with ustekinumab or adalimumab.
- Data from a large healthcare database was analyzed, comparing patient outcomes based on their prior treatment experience over a 12-month period.
- Results showed that patients naive to advanced therapy had higher persistence rates with ustekinumab compared to adalimumab, regardless of previous treatment history, indicating ustekinumab may be more effective for maintaining treatment adherence.
Objectives: To describe and compare healthcare resource utilization (HRU) among advanced therapy-naïve and advanced therapy-experienced patients with ulcerative colitis (UC) initiating ustekinumab or vedolizumab in the United States.
Methods: Claims data from IQVIA PharMetrics Plus de-identified database (01/01/2015-06/30/2022) were used to identify adult patients with UC initiating ustekinumab or vedolizumab (index date) after 10/21/2019. Baseline characteristics were balanced using inverse probability of treatment weighting.
Article Synopsis
- The study aimed to examine how long adults with ulcerative colitis (UC) continue treatment with either ustekinumab or adalimumab over a year, considering prior biologic use.
- It involved analyzing data from patients starting these medications between October 2019 and August 2021, focusing on their treatment persistence and conditions like being corticosteroid-free or on monotherapy after 12 months.
- Results indicated that patients initiated on ustekinumab showed higher persistence rates compared to those on adalimumab, particularly among bio-naïve individuals, and greater likelihood of remaining corticosteroid-free and on monotherapy.
Background: Chronic corticosteroid use is common in ulcerative colitis (UC); however, real-world evidence of its burden to the health care system is limited.
Objective: To quantify chronic corticosteroid use burden in UC.
Methods: Adults with UC initiated on targeted treatments (ie, biologics and advanced/small molecule therapies) or conventional therapy (index date) were selected from a deidentified US insurance claims database (January 1, 2004, to September 30, 2021).